

# Curriculum Vitae

Name : Chan, Yi-Hsin

Sex : Male

Birth Date : 1978/07/12

Birth Place : Taipei City Taiwan

Citizenship : Taiwan

e-mail : [s851047@hotmail.com](mailto:s851047@hotmail.com)

Language : Chinese, English

Education : 1996/07/01~2003/06/30, National Yang-Ming University, No.155, Sec.2, Linong Street, Taipei, 112 Taiwan

Academic Appointment ( Include Teaching Experience ) : NA

Employment Record : ( Date, Title, Department, Name of Hospital of Institutions, Location )

2005/08/01-2008/07/31, Resident, Internal Medicine, Chang Gung Memorial Hospital, Linkou

2008/08/01-2010/07/31, Chief Resident, First division of Cardiology, Linkou

2010/08/01- , Attending Physician, First division of Cardiology, Linkou

2012/10/01-2014/09/30, Research Fellow in Cardiac Electrophysiology, Indiana University-Purdue University Indianapolis, IN, USA

2015/07/01-2018/06/30, Assistant Professor of Internal Medicine and Cardiology, Chang Gung Memorial Hospital, Linkou

2018/07/01- , Associate Professor of Internal Medicine and Cardiology, Chang Gung Memorial Hospital, Linkou

2018/07/01- , Assistant Professor, Chang Gung University

2016/07/01- , Director, Microscopy Core Laboratory, Chang Gung Memorial Hospital, Linkou

2022/02/01- , Associate Professor, Chang Gung University

2023/07/01- , Professor of Internal Medicine and Cardiology, Chang Gung Memorial Hospital, Linkou

Board Certification : ( Date, Name of the Board , Certification NO. )

2009/03, Taiwan Society of Internal Medicine, No.8189

2010/11, Taiwan Society of Cardiology, No.s1390

2016/11 Taiwan Society of Heart Rhythm, No.0181

Professional Affiliations :

Taiwan Society of Internal Medicine

Taiwan Society of Cardiology

Research Interest :

Clinical Cardiology

Electrophysiology

Biophotonics

Computer model and simulation in cardiac electrophysiology

Biomedical signal analysis (ECG, EEG, respiratory signal, blood pressure, sleep data)

Laser scanning confocal microscopy

Optical mapping in whole heart and cardiovascular tissue

## **Publications: (只列出 First or Corresponding author)**

1. **Chan YH**, Chou C, Wu JS, Chang HF, Yau HF. Properties of a diffused photon-pair density wave in a multiple-scattering medium. *Appl Opt.* 2005 Mar 10;44(8):1416-25. **(SCI; IF=1.96, Optics 53/97)**
2. **Chan YH**, Wu CT, Yeh YH, Chi-Tai Kuo. Reappraisal of Luo-Rudy Dynamic Cell Model. *Acta Cardiol Sin* 2010;26:69-80.
3. **Chan YH**, Wu LS, Yeh YH, Wu CT, Wang CL, Luqman N, Chen WJ, Hsu TS, Kuo CT. Possible targets of therapy for catecholaminergic polymorphic ventricular tachycardia. - Insight from a theoretical model -. *Circ J.* 2011;75(8):1833-42. **(SCI ; IF=2.50; Cardiac & Cardiovascular Systems 64/138).**
4. **Chan YH**, Liew KP, Sun CC, Hsueh C, Li BC, Tsai FC, Lin JL, Chu PH. Hyperacute rejection from a donor who died of carbamate intoxication--a case report. *Am J Emerg Med.* 2012 Oct;30(8):1661.e1-4. **(SCI ; IF=1.91; Emergency Medicine 13/31)**
5. **Chan YH**, Kuo CT, Yeh YH, Wu LS, Wang CL, Ho WJ, Hsu LA. Incremental value of radial discoordination index for the prediction of response to cardiac resynchronization therapy. *Eur Heart J Cardiovasc Imaging.* 2013 Mar;14(3):213-22. **(SCI; IF=4.841; Cardiac & Cardiovascular Systems 28/138).**
6. **Chan YH**, Wu LS, Kuo CT, Wang CL, Yeh YH, Ho WJ, Hsu LA. Incremental value of inefficient deformation indices for predicting response to cardiac resynchronization therapy. *J Am Soc Echocardiogr.* 2013 Mar;26(3):307-15. **(SCI ; IF=5.508; Cardiac & Cardiovascular Systems 28/138).**
7. **Chan YH**, Wang CL, Kuo CT, Yeh YH, Wu CT, Wu LS. Clinical Assessment and Implication of Left Ventricular Mechanical Dyssynchrony in Patients with Heart Failure. *Acta Cardiol Sin.* 2013 Nov;29(6):505-14.
8. **Chan YH**, Tsai WC, Song Z, Ko CY, Qu Z, Weiss JN, Lin SF, Chen PS, Jones LR, Chen Z\*. Acute reversal of phospholamban inhibition facilitates the rhythmic whole-cell propagating calcium waves in isolated ventricular myocytes. *J Mol Cell Cardiol.* 2015 Mar; 80:126-35. **(SCI; IF=5.68, Cardiac & Cardiovascular Systems 20/125)**
9. **Chan YH**, Tsai WC, Shen C, Han S, Chen LS, Lin SF, Chen PS\*. Subcutaneous nerve activity is more accurate than the heart rate variability in estimating cardiac sympathetic tone in ambulatory dogs with myocardial infarction. *Heart Rhythm.* 2015 Mar 13. **(SCI ; IF=5.731 ; Cardiac & Cardiovascular Systems 19/138 )**
10. **Chan YH**, Tsai WC, Chang PC, Weiss JN, Lin SF, Chen PS. Small Conductance Calcium-

Activated Potassium Current is Activated During Hypokalemia and Masks Short Term Cardiac Memory Induced by Ventricular Pacing Circulation. 2015 Oct 13;132(15):1377-86 (**SCI; IF=23.60, Cardiac & Cardiovascular Systems 1/138**)

11. **Chan YH**, Kuo CT, Wu LS, Wang CL, Yeh YH, Hsu LA, Ho WJ. Combined Global Longitudinal Strain and Intraventricular Mechanical Dyssynchrony Predicts Long-Term Outcome in Patients With Systolic Heart Failure. *Circ J*. 2016; 80(1):177-85. (**SCI ; IF=3.544; Cardiac & Cardiovascular Systems 31/123**)
12. **Chan YH\***; **Yen KC\***; See LC, PhD; Chang SH; Wu LS; Lee HF; Tu HT; Yeh YH; Kuo CT. Cardiovascular, bleeding, and mortality risks of Dabigatran in Asians with Non-valvular Atrial Fibrillation. *Stroke*. 2016. 47(2):441-9 (**SCI; IF=7.19; Clinical Neurology 16/204**)
13. **Chan YH\***, **Kuo CT\***, Yeh YH, Chang SH, Wu LS, Lee HS, Tu HT, See LC. Thromboembolic, Bleeding and Mortality Risks of Rivaroxaban and Dabigatran in Asians with Non-valvular Atrial Fibrillation. *JACC*. 2016. Sep 27;68(13):1389-401 (**SCI ; IF=20.59; Cardiac & Cardiovascular Systems 3/138**)
14. **Chan YH**, Yeh YH, See LC, Wang CL, Chang SH, Lee HF, Wu LSh, Tu HT, Kuo CT. The Risk of Acute Kidney Injury in Asians Treated with Dabigatran or Warfarin for Non-valvular Atrial Fibrillation: A Nationwide Cohort Study in Taiwan. *JACC*. 2016, Nov 29;68(21):2272-2283 (**SCI ; IF=20.59; Cardiac & Cardiovascular Systems 3/138**)
15. **Chan YH\***, **Yeh YH\***, Tu HT, Kuo CT, Chang SH, Wu LS, Lee HF, See LC. Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation. *Oncotarget*. 2017 Oct 24;8(58):98898-98917.
16. **Chan YH**; Lee HF, MD; Wu LS, MD; Wang CL; Wu CT; Yeh, YH; Ho WJ; Hsu LA; Chu PH; Kuo CT. Ratio of Transmitral Early Filling Velocity to Early Diastolic Strain Rate Predicts Outcomes in Patients with Systolic Heart Failure. *Eur Heart J Cardiovasc Imaging* (2017) 18 (1): 79-85 (**SCI ; IF=5.99 ; Cardiac & Cardiovascular Systems 26/123**)
17. **Lee HF, Chan YH(共同第一)**, Tu HT, Kuo CT, Yeh YH, Chang SH, Wu LS, See LC\*.The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation. *Int J Cardiol*. 2018 Jun 15;261:78-83. (SCI; IF= 4.039, Cardiac & Cardiovascular Systems 60/143)
18. **Chan YH**, See LC, Tu HT, Yeh YH, Chang SH, Wu LS, Lee HF, Wang CL, Kuo CF\*, Kuo CT\*. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation. *J Am Heart Assoc*. 2018 Apr 5;7(8):e008150. (SCI ; IF=6.106 ; Cardiac & Cardiovascular Systems 42/143 )
19. **Chan YH**, Yeh YH, Hsieh MY, Chang CY, Tu HT, Chang SH, See LC, Kuo CF, Kuo CT\*. The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan *Int J Cardiol*. 2018 Aug 15;265:83-89. (SCI ; IF=4.039 ; Cardiac & Cardiovascular Systems 60/143 )
20. **Lee HF, Chan YH(共同第一)**, Chang SH, Tu HT, Chen SW, Yeh YH, Wu LS, Kuo CF, Kuo CT, See LC\*. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation. *J Am Heart Assoc*. 2019 Mar 5;8(5):e011112. (SCI ; IF=6.106 ; Cardiac & Cardiovascular Systems 42/143 )
21. **Chan YH, Lee KT(共同第一)**, Kao YW, Huang CY, Chen YL, Hang SC, Chu PH\*. The

- comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular atrial fibrillation. **PLoS One**. 2019 Mar 18;14(3):e0213517. (SCI ; IF=3.752; Multidisciplinary sciences 29/73 )
22. **Chan YH, Lee HF (共同第一)**, See LC, Tu HT, Chao TF, Yeh YH, Wu LS, Kuo CT\*, Chang SH, Lip GYH. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. **Chest**. 2019 Sep;156(3): 529-543. (SCI ; IF=10.26 ; Respiratory Systems, 6/65 )
  23. **Chan YH**, Chang GJ, Lai YJ, Chen WJ, Chang SH, Hung LM, Kuo CT\*, Yeh YH\*. Atrial fibrillation and its arrhythmogenesis associated with insulin resistance. **Cardiovasc Diabetol**. 2019 Sep 26;18(1):125 (SCI ; IF=8.949 ; Endocrinology & Metabolism 15/146 )
  24. **Chan YH**, Lee HF, Wang CL, Chang SH, Yeh CH, Chao TF\*, Yeh YH, Chen SA, Kuo CT. Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation. **J Am Heart Assoc**. 2019 Nov 5;8(21):e013053. (SCI ; IF=6.106 ; Cardiac & Cardiovascular Systems 42/143 )
  25. Lee HF, See LC, Li PR, Liu JR, Chao TF, Chang SH, Wu LS, Yeh YH, Kuo CT, **Chan YH\*(共同指導作者)**, **Lip GYH\***. Non-Vitamin K Antagonist Oral Anticoagulants and Warfarin in Atrial Fibrillation Patients with Concomitant Peripheral Artery Disease. **Eur Heart J Cardiovasc Pharmacother**. 021 Jan 16;7(1):50-58.(SCI ; IF=11.177 ; Pharmacology & Pharmacy 14/279)
  26. **Chan YH**, Lee HF, Chao TF, Wu CT, Chang SH, Yeh YH, See LC, Kuo CT, Chu PH, Wang CL\*, Lip GYH\*. Real-world Comparisons of Direct Oral Anticoagulants for Stroke Prevention in Asian Patients with Non-valvular Atrial Fibrillation: a Systematic Review and Meta-analysis. **Cardiovasc Drugs Ther**. 2019 Dec;33(6):701-710. (SCI ; IF=3.947 ; Cardiac & Cardiovascular Systems 63/143)
  27. Lee HF, **Chan YH**, Li PR, Liu JR, Chao TF, Wu LS, Chang SH, Yeh YH, Kuo CT, See LC\*, Lip GYH\*. Oral Anticoagulants and Antiplatelet Agents in Patients With Atrial Fibrillation and Concomitant Critical Limb Ischemia: A Nationwide Cohort Study. **Can J Cardiol**. 2020 Feb 19:S0828-282X(20)30175-6. (SCI ; IF=6.614 ; Cardiac & Cardiovascular Systems 37/143)
  28. **Chan YH, Chuang C(共同第一)**, Chan CC, Lee HF, Huang YC, Huang YT, Chang SH, Wang CL, Chao TF\*, Kuo CT, Yeh YH, Chen SA. Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation. **Cardiovasc Diabetol**. 2020 Mar 10;19(1):30. (SCI ; IF=8.949 ; Endocrinology & Metabolism 15/146 )
  29. **Chan YH**, Lee HF, Li PR, Liu JR, Chao TF, Wu LS, Chang SH, Yeh YH, Kuo CT, See LC\*, Lip GYH\*. Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants. **Cardiovasc Diabetol**. 2020 May 13;19(1):63. (SCI ; IF=8.949 ; Endocrinology & Metabolism 15/146 )
  30. **Chan YH, Hsu TJ(共同第一)**, Wang CL, Kao YW, Huang CY, Chu PH\*.Sodium glucose cotransporter-2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function. **ESC Heart Fail**. 2020 Jul 6;7(5):2784-96. doi: 10.1002/ehf2.12877. (SCI ; IF=3.612 ; Cardiac & Cardiovascular Systems 68/143)
  31. **Chan YH**, Chao TF\*, Chen SW, Lee HF, Yeh YH, Huang YC, Chang SH, Kuo CT, Lip GYH,

- Chen SA. Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation. *Heart Rhythm*. 2020 Jul 20:S1547-5271(20)30678-0. doi:10.1016/j.hrthm. 2020.07.022. (SCI ; IF=6.779 ; Cardiac & Cardiovascular Systems 36/143 )
32. **Chan YH, Wu LS(共同第一)**, See LC, Liu JR, Chang SH, Chao TF, Yeh YH, Kuo CT, Lee HF\*, Lip GYH\*. Direct Oral Anticoagulants in Atrial Fibrillation Patients With Concomitant Hyperthyroidism. *J Clin Endocrinol Metab*. 2020 Sep 1;105(9):dgaa050. doi: 10.1210/clinem/dgaa050. (SCI ; IF=6.134 ; Endocrinology & Metabolism 32/146 )
33. Lee HF, Chen SW, Liu JR, Li PR, Wu LS, Chang SH, Yeh YH, Kuo CT, **Chan YH\*(共同指導作者)**, **See LC\***. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor. *Cardiovasc Diabetol*. 2020 Sep 30;19(1):160. (SCI ; IF=8.949 ; Endocrinology & Metabolism 15/146)
34. **Chan YH**, Chao TF\*, Lee HF, Yeh YH, Yeh CH, Huang YC, Chang SH, Kuo CT, Lip GYH, Chen SA. Impacts of Different Renal Function Estimation Formulas on Dosing of DOACs and Clinical Outcomes. *J Am Coll Cardiol*. 2020 Oct 13;76(15):1808-1810. (SCI ; IF=27.304 ; Cardiac & Cardiovascular Systems 5/143)
35. Ling AWC, Chan CC, Chen SW, Kao YW, Huang CY, **Chan YH\*(共同指導作者)**, **Chu PH\*** The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. *Cardiovasc Diabetol*. 2020. Nov 6;19(1):188. (SCI ; IF=8.949 ; Endocrinology & Metabolism 15/146)
36. See LC, Lee HF, Chao TF, Li PR, Liu JR, Wu LS, Chang SH, Yeh YH, Kuo CT, **Chan YH\*(共同指導作者)**, **Lip GYH\***. Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis. *Cardiovasc Drugs Ther*. 2021 Oct;35(5):975-986. doi: 10.1007/s10557-020-07108-4. (SCI ; IF=3.947 ; Cardiac & Cardiovascular Systems 63/143 )
37. **Chao TF\***, **Chan YH(共同第一)**, Chiang CE, Tuan TC, Liao JN, Chen TJ, Lip GYH, Chen SA. Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation. *Clin Res Cardiol*. 2021 Mar 11. doi: 10.1007/s00392-021-01816-z. (SCI ; IF=6.138 ; Cardiac & Cardiovascular Systems 40/143 )
38. **Chan YH**, Chen SW, Chao TF, Kao YW, Huang CY, Chu PH\*. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor. *Cardiovasc Diabetol*. 2021 Apr 30;20(1):93. doi: 10.1186/s12933-021-01285-8. (SCI ; IF=8.949 ; Endocrinology & Metabolism 15/146 )
39. **Chang SH, Chan YH(共同第一)**, Chen WJ\*, Chang GJ, Lee JL, Yeh YH. Tachypacing-induced CREB/CD44 signaling contributes to the suppression of L-type calcium channel expression and the development of atrial remodeling. *Heart Rhythm*. 2021 May 20:S1547-5271(21)00448-3. doi: 10.1016/j.hrthm.2021.05.021. (SCI ; IF=6.779 ; Cardiac & Cardiovascular Systems 36/143 )
40. **Chan YH**, Chen SW, Chao TF, Kao YW, Huang CY, Chu PH\*. Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors. *Diabetes Obes Metab*. 2021 2021 Sep;23(9):2077-2089. doi:

- 10.1111/dom.14446. (SCI ; IF=6.410 ; Endocrinology & Metabolism 30/146 )
41. **Cheng WH, Chan YH(共同第一)**, Liao JN, Kuo L, Chen SA, Chao TF\*. Optimal Management of Anticoagulation Therapy in Asian Patients With Atrial Fibrillation. *Circ J*. 2021 Jul 21;85(8):1245-1253. doi: 10.1253/circj.CJ-21-0399. (SCI ; IF=3.350 ; Cardiac & Cardiovascular Systems 72/143 )
  42. **Kuo L, Chan YH(共同第一)**, Liao JN, Chen SA, Chao TF\*. Stroke and Bleeding Risk Assessment in Atrial Fibrillation: Where Are We Now? *Korean Circ J*. 2021 Aug;51(8): 668-680. doi: 10.4070/kcj.2021.0170. (SCI ; IF=3.101 ; Cardiac & Cardiovascular Systems 83/143 )
  43. **Chan YH, Chao TF(共同第一)**, Lee HF, Chen SW, Li PR, Liu JR, Wu LS, Chang SH, Yeh YH, Kuo CT, See LC\*, Lip GYH\*. Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study. *Stroke*. 2021 Oct;52(10):3132-3141. doi: 10.1161/STROKEAHA.120.033470. (SCI ; IF=10.170 ; Clinical Neurology 16/208 )
  44. **Chao TF\*, Chan YH(共同第一)**, Tuan TC, Liao JN, Chen TJ, Lip GYH, Chen SA. Should oral anticoagulants still be prescribed to patients with atrial fibrillation with a single stroke risk factor but at high bleeding risk? a nationwide cohort study. *Eur Heart J Qual Care Clin Outcomes*. 2021 Jul 24;qcab050. doi: 10.1093/ehjqcco/qcab050 (SCI ; IF=7.064 ; Cardiac & Cardiovascular Systems 32/143 )
  45. **Chan YH**, Chen SW, Chao TF, Kao YW, Huang CY, Chu PH\*. The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors. *Cardiovasc Diabetol*. 2021 Aug 16;20(1):167. doi: 10.1186/s12933-021-01361-z. (SCI ; IF=8.949 ; Endocrinology & Metabolism 15/146 )
  46. Lee HF, Cheng YW, Peng JR, Hsu CY, Yang CH, **Chan YH(共同指導作者)\***, **Chu PH(共同指導作者)\***. Impact of chronic kidney disease on long-term outcomes for coronary in-stent restenosis after drug-coated balloon angioplasty. *J Cardiol*. 2021 Aug 25:S0914-5087(21)00206-9. doi: 10.1016/j.jcc.2021.08.010. Online ahead of print. (SCI ; IF=2.974 ; Cardiac & Cardiovascular Systems 84/143 )
  47. **Chao TF\*, Chan YH(共同第一)**, Chiang CE, Tuan TC, Liao JN, Chen TJ, Gregory Y H Lip, Chen SA. Stroke prevention with direct oral anticoagulants in high risk elderly atrial fibrillation patients at increased bleeding risk *Eur Heart J Qual Care Clin Outcomes*. 2021 Oct 25;qcab076. doi: 10.1093/ehjqcco/qcab076.(SCI ; IF=7.064 ; Cardiac & Cardiovascular Systems 32/143 )
  48. **Huang JT, Chan YH(共同第一)**, Wu VC, Cheng YT, Chen DY, Lin CP, Hung KC, Chang SH, Chu PH, Chou AH, Chen SW\*. Analysis of Anticoagulation Therapy and Anticoagulation-Related Outcomes Among Asian Patients After Mechanical Valve Replacement. *JAMA Network Open*. 2022 Feb 1;5(2):e2146026. doi: 10.1001/jamanetworkopen.2021.46026. (SCI ; IF=13.366 ; MEDICINE, GENERAL & INTERNAL 15/172 )
  49. **Liao JN, Chan YH(共同第一)**, Kuo L, Tsai CT, Lim SS, Chao TF. Optimal anticoagulation in elderly patients with atrial fibrillation: Which drug at which dose? *Kardiol Pol*. 2022;80(2):128-136. (SCI ; IF=3.710 ; Cardiac & Cardiovascular Systems 66/143 )
  50. **Chao TF, Chan YH(共同第一)**, Chiang CE, Tuan TC, Liao JN, Chen TJ, Lip GY, Chen SA. Early rhythm control and the risks of ischaemic stroke, heart failure, mortality and adverse events

- when performed early (<3 months). **Thromb Haemost.** 2022 Mar 23. doi: 10.1055/a-1807-0336. Online ahead of print. (SCI ; IF=6.681 ; Peripheral vascular disease 12/67 )
51. Yeh YH, **Chan YH**, Chen SW, Chang SH, Wang CL, Kuo CT, Lip GYH, Chen SA, Chao TF. Oral Anticoagulant Use for Patients with Atrial Fibrillation with Concomitant Anemia and / or Thrombocytopenia. **Am J Med.** 2022 Aug;135(8):e248-e256.(SCI ; IF=5.928 ; Medicine, General & Internal SCIE 36/172 )
  52. **Chan YH**, Chao TF, Chen SW, Lee HF, Li PR, Chen WM, Yeh YH, Kuo CT, See LC, Lip GYH. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. **Cardiovasc Diabetol.** 2022 Jun 28;21(1):118. (SCI ; IF=8.949 ; Endocrinology & Metabolism 15/146 )
  53. Hsiao FC, Yen KC, Chao TF, Chen SW, **Chan YH (co-corresponding author)\***, **Chu PH (co-corresponding author)\***. New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies. **J Clin Endocrinol Metab.** 2022 Aug 18;107(9):2493-2499. (SCI ; IF=6.134 ; Endocrinology & Metabolism 32/146 )
  54. **Chan YH\***, Chao TF, Chen SW, Kao YW, Huang CY, Chu PH\*. Association of acute increases in serum creatinine with subsequent outcomes in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor or dipeptidyl peptidase-4 inhibitor. **Eur Heart J Qual Care Clin Outcomes.** 2022 Jul 7:qcac040.(SCI ; IF=7.064 ; Cardiac & Cardiovascular Systems 32/143 )
  55. **Liao JN, Chan YH(共同第一)**, Kuo L, Tsai CT, Lim SS, Chao TF.\* Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants. **Front Cardiovasc Med.** 2022 Jul 5;9:874460. (SCI ; IF=5.846 ; Cardiac & Cardiovascular Systems 43/143 )
  56. **Chan YH**, Chao TF, Chen SW, Lee HF, Li PR, Chen WM, Yeh YH, Kuo CT, See LC\*, Lip GYH. Development of Interstitial Lung Disease Among Patients with Atrial Fibrillation Treated with Oral Anticoagulants in Taiwan. **JAMA Netw Open.** 2022 Nov 1;5(11):e2243307. (SCI ; IF=13.366 ; Medicine, General & Internal SCIE 15/172 )
  57. Lee HF, Chuang C, Li PR, Yeh YH, **Chan YH (指導作者)**, See LC. Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. **Diabetol Metab Syndr.** 2023 Jan 18;15(1):8. doi: 10.1186/s13098-023-00982-6. (SCI ; IF=5.395 ; Endocrinology & Metabolism 42/146 )
  58. **Chan YH (第一兼指導作者)**, Chao TF, Chen SW, Kao YW, Huang CY, Chu PH. The Association of Background Medications on Initial eGFR Change and Kidney Outcomes in Diabetic Patients Receiving SGLT2 Inhibitor. **Clin J Am Soc Nephrol.** 2023 Mar 31. (SCI ; IF=10.67 ; UROLOGY & NEPHROLOGY SCIE 7/90 )
  59. Liu SH, Chao TF, **Chan YH (指導作者)**, Liao JN, Chen TJ, Lip GYH, Chen SA. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study. **Europace.** 2023 May 5:eua120. (SCI ; IF=5.486 ; Cardiac & Cardiovascular Systems 46/143 )

## Patent

1. Chou, Chien, Chan, Yi-Hsin, Wu, Jheng-Syong, "Method for measuring the absorption coefficient and the reduced scattering coefficient of a multiple scattering medium," United States Patent 7,230,716, 2007
2. Chou, Chien, Chan, Yi-Hsin, Wu, Jheng-Syong, Yu, Li-ping, "Method and apparatus for measuring the absorption coefficient and the reduced scattering coefficient of a multiple scattering medium," United States Patent 7,333,212, 2008
3. Lu, Jang-Jih; Chen Chun-Hsien; Wang, Hsin-Yao; Chan, Yi-Hsin; Shih, Wei-Shang, "CORONARY ARTERY DISEASE SCREENING METHOD BY USING CARDIOVASCULAR MARKERS AND MACHINE LEARNING ALGORITHMS" United States Patent 0221309, 2019.